Literature DB >> 33289661

Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors.

Mark Rochman1, Yong Mei Xie1, Lydia Mack1, Julie M Caldwell1, Andrea M Klingler1, Garrett A Osswald1, Nurit P Azouz2, Marc E Rothenberg3.   

Abstract

BACKGROUND: Proton pump inhibitors (PPIs) have been recognized as a primary treatment of eosinophilic esophagitis (EoE), an allergic inflammatory disease of the esophageal mucosa. The mechanisms underlying esophageal epithelial responses to PPIs remain poorly understood.
OBJECTIVE: We hypothesized that PPIs can counteract IL-13-mediated esophageal epithelial responses that are germane for EoE pathogenesis.
METHODS: Transcriptional responses of human esophageal cells to IL-13 and the PPIs omeprazole and esomeprazole were assessed by RT-PCR and RNA sequencing. Cytokine secretion was measured by multiplex analysis and ELISA.
RESULTS: Human esophageal epithelial cells robustly responded to PPI stimulation by inducing a set of 479 core genes common between omeprazole and esomeprazole treatments. The transcriptional response to PPIs was partially mediated through the aryl hydrocarbon receptor signaling pathway, as the aryl hydrocarbon receptor antagonist GNF-351 modified approximately 200 genes, particularly those enriched in metabolic processes and regulation of cell death. PPI treatment reversed approximately 20% of the IL-13 transcriptome. Functional analysis of the PPI-responsive, upregulated genes revealed enrichment in metabolic and oxidation processes, and the unfolded protein response. In contrast, downregulated genes were overrepresented in functional terms related to cell division and cytoskeletal organization, which were also enriched for the genes in the EoE transcriptome reversed by PPIs. Furthermore, PPI treatment decreased the IL-13-induced proliferative response of esophageal epithelial cells.
CONCLUSIONS: These results demonstrate broad effects of PPIs on esophageal epithelium, including their ability to curtail transcriptomic processes involved in cellular proliferation and IL-13-induced responses, and they highlight the importance of AHR signaling in mediating these responses.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-13; Proton pump inhibitors; aryl hydrocarbon receptor; eosinophilic esophagitis; epithelium; esomeprazole; omeprazole

Mesh:

Substances:

Year:  2020        PMID: 33289661      PMCID: PMC8062577          DOI: 10.1016/j.jaci.2020.09.039

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

1.  Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk.

Authors:  Tetsuo Shoda; Ting Wen; Julie M Caldwell; Netali Ben-Baruch Morgenstern; Garrett A Osswald; Mark Rochman; Lydia E Mack; Jennifer M Felton; J Pablo Abonia; Nicoleta C Arva; Dan Atkins; Peter A Bonis; Kelley E Capocelli; Margaret H Collins; Evan S Dellon; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; John Leung; Paul A Menard-Katcher; Vincent A Mukkada; Philip E Putnam; Amanda K Rudman Spergel; Jonathan M Spergel; Joshua B Wechsler; Guang-Yu Yang; Seema S Aceves; Glenn T Furuta; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2021-10-21       Impact factor: 22.682

2.  Associations Between Asthma Diagnosis/Asthma Exacerbation and Previous Proton-Pump Inhibitor use: A Nested Case-Control Study Using a National Health Screening Cohort.

Authors:  Hyo Geun Choi; Chanyang Min; Dae Myoung Yoo; Bruce K Tan; Joo-Hee Kim; Hwan Il Kim; Ji-Young Park; Sunghoon Park; Yong Il Hwang; Seung Hun Jang; Ki-Suck Jung
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

3.  Long-term efficacy of proton pump inhibitors as a treatment modality for eosinophilic esophagitis.

Authors:  Kisan P Thakkar; Mark Fowler; Staci Keene; Alina Iuga; Evan S Dellon
Journal:  Dig Liver Dis       Date:  2022-04-08       Impact factor: 5.165

Review 4.  Mechanisms and clinical management of eosinophilic oesophagitis: an overview.

Authors:  Luc Biedermann; Alex Straumann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-10-17       Impact factor: 73.082

Review 5.  Drug Reaction with Eosinophilia and Systemic Symptoms: A Complex Interplay between Drug, T Cells, and Herpesviridae.

Authors:  Luckshman Ganeshanandan; Michaela Lucas
Journal:  Int J Mol Sci       Date:  2021-01-23       Impact factor: 5.923

Review 6.  Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions.

Authors:  James P Franciosi; Edward B Mougey; Evan S Dellon; Carolina Gutierrez-Junquera; Sonia Fernandez-Fernandez; Rajitha D Venkatesh; Sandeep K Gupta
Journal:  J Asthma Allergy       Date:  2022-02-26

Review 7.  Human Microbiota in Esophageal Adenocarcinoma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Implications.

Authors:  Wanyue Dan; Lihua Peng; Bin Yan; Zhengpeng Li; Fei Pan
Journal:  Front Microbiol       Date:  2022-01-14       Impact factor: 5.640

8.  Single-cell RNA-Seq of human esophageal epithelium in homeostasis and allergic inflammation.

Authors:  Mark Rochman; Ting Wen; Michael Kotliar; Phillip J Dexheimer; Netali Ben-Baruch Morgenstern; Julie M Caldwell; Hee-Woong Lim; Marc E Rothenberg
Journal:  JCI Insight       Date:  2022-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.